Status:
RECRUITING
68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
Lead Sponsor:
Kunwei Shen
Conditions:
BREAST CANCER
PET/CT
Eligibility:
FEMALE
18+ years
Brief Summary
The goal of this observational study is to learn whether 68Ga-FAPI PET/CT may be used as a new effective methods for evaluating axillary lymph node efficacy after neoadjuvant treatment for breast canc...
Detailed Description
Previous studies have shown that compared with conventional 18F-FDG PET/CT, 68Ga-FAPI PET/CT has the characteristics of not being affected by blood glucose, good tumor specificity, and high tumor-to-b...
Eligibility Criteria
Inclusion
- Female patients aged 18 and above
- ECOG score 0-2 points
- Pathological confirmation of malignant breast tumor
- Clinical axillary lymph node positivity (cN+)
- Completed at least 3 courses of neoadjuvant therapy and subjected to undergo surgical treatment
- Informed consent form signed
Exclusion
- Distant metastasis
- Unable to complete the proposed neoadjuvant therapy plan
- Pregnancy
Key Trial Info
Start Date :
August 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06559371
Start Date
August 30 2024
End Date
June 30 2026
Last Update
December 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200020